

Jorge Hernández Vara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6764188/publications.pdf>

Version: 2024-02-01

70
papers

1,864
citations

279798

23
h-index

302126

39
g-index

85
all docs

85
docs citations

85
times ranked

2504
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. <i>Movement Disorders</i> , 2008, 23, 1130-1136.	3.9	212
2	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 13-20.	2.2	149
3	Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study. <i>Movement Disorders</i> , 2012, 27, 211-218.	3.9	105
4	Nonmotor Symptoms in LRRK2 G2019S Associated Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e108982.	2.5	79
5	Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 871-876.	2.2	79
6	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 151-157.	2.2	71
7	COPPADIS-2015 (COhort of Patients with Parkinson's Disease in Spain, 2015), a global "clinical evaluations, serum biomarkers, genetic studies and neuroimaging" prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016, 16, 26.	1.8	66
8	α -Synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1024-1032.	3.7	63
9	The association of apathy with central fatigue perception in patients with Parkinson's disease.. <i>Behavioral Neuroscience</i> , 2013, 127, 237-244.	1.2	46
10	Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study. <i>Movement Disorders</i> , 2016, 31, 1820-1828.	3.9	45
11	Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1170-1176.	2.2	43
12	A Kinematic Sensor and Algorithm to Detect Motor Fluctuations in Parkinson Disease: Validation Study Under Real Conditions of Use. <i>JMIR Rehabilitation and Assistive Technologies</i> , 2018, 5, e8.	2.2	43
13	Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2020, 27, 1210-1223.	3.3	40
14	A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. <i>Frontiers in Neurology</i> , 2021, 12, 705407.	2.4	36
15	Age at Onset in LRRK2-Associated PD is Modified by SNCA Variants. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 245-247.	2.3	34
16	Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2011, 32, 547.e11-547.e16.	3.1	32
17	Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion. <i>Brain and Behavior</i> , 2017, 7, e00758.	2.2	32
18	Discovering the 3' UTR-mediated regulation of alpha-synuclein. <i>Nucleic Acids Research</i> , 2017, 45, 12888-12903.	14.5	32

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 16-23.	2.2	32
20	COPPADIS 2015 Cohort of Patients with Parkinson's Disease: 1000 subjects included. Results from the baseline evaluation. <i>European Journal of Neurology</i> , 2019, 26, 1399-1407.	3.3	32
21	Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges. <i>Annals of Neurology</i> , 2018, 84, 347-360.	5.3	31
22	Quantitative Evaluation of Striatal I-123-FP-CIT Uptake in Essential Tremor and Parkinsonism. <i>Clinical Nuclear Medicine</i> , 2011, 36, 991-996.	1.3	29
23	Attention-deficit hyperactivity disorder in chronic fatigue syndrome patients. <i>Psychiatry Research</i> , 2012, 200, 748-753.	3.3	28
24	Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 3-12.	2.2	26
25	SNCA but not dynamin 3 influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. <i>Movement Disorders</i> , 2018, 33, 637-641.	3.9	25
26	Does reduced [123I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement?. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 870-875.	1.4	22
27	Reversible hemichorea associated with extracranial carotid artery stenosis. <i>Journal of the Neurological Sciences</i> , 2011, 300, 185-186.	0.6	21
28	Impaired proteasome activity and neurodegeneration with brain iron accumulation in FBXO7 defect. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1436-1442.	3.7	21
29	Relationship between poor decision-making process and fatigue perception in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2014, 337, 167-172.	0.6	20
30	Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. <i>Journal of Neurology</i> , 2011, 258, 1055-1057.	3.6	18
31	Predictors of clinically significant quality of life impairment in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 118.	5.3	17
32	In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 68-75.	2.2	16
33	MicroRNA Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways. <i>Movement Disorders</i> , 2020, 35, 1873-1879.	3.9	15
34	Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1611-1620.	2.8	15
35	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. <i>Neurological Sciences</i> , 2020, 41, 2883-2892.	1.9	13
36	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120148.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, e32-e32.	3.3	12
38	Remote control of apomorphine infusion rate in Parkinson's disease: Real-time dose variations according to the patients' motor state. A proof of concept. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 996-998.	2.2	12
39	Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up. <i>Journal of Clinical Medicine</i> , 2021, 10, 1664.	2.4	12
40	Unexpected I-123 FP-CIT Uptake in a Brain Tumor. <i>Clinical Nuclear Medicine</i> , 2009, 34, 608-609.	1.3	11
41	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2019, 126, 1599-1608.	2.8	11
42	BDNF levels and nigrostriatal degeneration in α -synuclein Parkinson's disease patients. An <i>in vivo</i> study using I-123-FP-CIT SPECT. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 31-35.	2.2	11
43	Parkinsonism related to Percheron artery infarct. <i>Journal of the Neurological Sciences</i> , 2017, 373, 21-22.	0.6	10
44	Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry. <i>Journal of Parkinson's Disease</i> , 2021, 11, 685-694.	2.8	10
45	Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. <i>Parkinson's Disease</i> , 2021, 2021, 1-16.	1.1	10
46	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 626.	2.5	10
47	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. <i>Journal of Parkinson's Disease</i> , 2022, 12, 315-331.	2.8	10
48	Depression is Associated with Impulse-compulsive Behaviors in Parkinson's disease. <i>Journal of Affective Disorders</i> , 2021, 280, 77-89.	4.1	9
49	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. <i>Diagnostics</i> , 2021, 11, 1801.	2.6	9
50	Transcriptomic differences in MSA clinical variants. <i>Scientific Reports</i> , 2020, 10, 10310.	3.3	7
51	Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ON, <i>Neurologia</i> , 2023, 38, 326-333.	0.7	7
52	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. <i>BMC Neurology</i> , 2021, 21, 477.	1.8	7
53	Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	7
54	Progressive Presynaptic Dopaminergic Deterioration in Huntington Disease. <i>Clinical Nuclear Medicine</i> , 2014, 39, e227-e228.	1.3	6

#	ARTICLE	IF	CITATIONS
55	Childhood trauma in Chronic Fatigue Syndrome: focus on personality disorders and psychopathology. <i>Comprehensive Psychiatry</i> , 2015, 62, 13-19.	3.1	6
56	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. <i>Scientific Reports</i> , 2020, 10, 16893.	3.3	6
57	Nigrostriatal pathway dysfunction in a methanol-induced delayed dystonia-parkinsonism. <i>Movement Disorders</i> , 2012, 27, 1220-1221.	3.9	5
58	Falls Predict Acute Hospitalization in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, , 1-20.	2.8	5
59	Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol. <i>BMJ Open</i> , 2021, 11, e045272.	1.9	5
60	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study. <i>Diagnostics</i> , 2022, 12, 1147.	2.6	5
61	Utilidad de la sonografía del parénquima cerebral en la enfermedad de Parkinson: Estudio comparativo con 123I-FP-CIT SPECT. <i>Medicina Clínica</i> , 2008, 131, 285-289.	0.6	4
62	Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Parkinson's Disease</i> , 2022, 12, 935-955.	2.8	3
63	Smoking is associated with age at disease onset in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 79-83.	2.2	2
64	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Diagnostics</i> , 2021, 11, 2380.	2.6	2
65	Ataxia por déficit de vitamina E en una familia con posible afectación cardíaca. <i>Neurología</i> , 2021, 36, 92-94.	0.7	1
66	Galactosemia Diagnosis by Whole Exome Sequencing Later in Life. <i>Movement Disorders Clinical Practice</i> , 2021, 8, S37-S39.	1.5	1
67	Genetic landscape of Segawa disease in Spain. Long-term treatment outcomes. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 67-78.	2.2	1
68	Síndrome corticobasal: un caso de discordancia entre la clínica y los biomarcadores de imagen. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2021, 41, 52-52.	0.0	0
69	Commentary: Galactosemia Diagnosis by Whole Exome Sequencing Later in Life. <i>Movement Disorders Clinical Practice</i> , 2021, 8, S40-S41.	1.5	0
70	Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol. <i>BMJ Open</i> , 2021, 11, e045272.	1.9	0